Physician profile
Julio Andres Barcena
NPI 1013111921
$37,426.26
in general payments reported to CMS, 2019-2025
41 companies · $3,462 in 2025
The $3,462 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $1,812 · 2021: $2,505 · 2022: $3,388 · 2023: $4,157 · 2024: $3,318 · 2025: $3,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,917.01 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15,411.00 | 2019-2025 | |
| Medtronic, INC. | $9,844.58 | 2021-2025 | Cobalt Dr Mri Surescan, Micra, Aurora Ev-Icd Mri Surescan |
| Medtronic Vascular, INC. | $2,702.40 | 2019-2020 | |
| Abbott Laboratories | $1,856.07 | 2019-2024 | Ensite Precision, Ensite, Navitor |
| E.R. Squibb & Sons, L.L.C. | $915.19 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $761.03 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $668.93 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $633.60 | 2021-2025 | |
| Boston Scientific Corporation | $573.16 | 2022-2025 | Watchman Flx, General - Therapies |
| Astrazeneca Pharmaceuticals Lp | $512.19 | 2019-2025 | Wainua, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $447.17 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $398.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Actelion Pharmaceuticals US, INC. | $330.02 | 2019-2024 | Opsumit, Uptravi |
| Impulse Dynamics (USA) INC. | $299.66 | 2021-2025 | Optimizer, Optimizer |
| Amgen INC. | $257.03 | 2019-2024 | Repatha |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Barcena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.